Biological therapies used in psoriasis treatment pose a risk of reactivation of hepatitis B virus
(HBV) infection. This risk occurs not only in patients with HB surface antigen (HBsAg)(+) but …

Abstract Background and Objectives Ustekinumab is used to treat moderate-to-severe
psoriasis by blocking the interleukin-12/23 pathway, which is also essential against …

Background Patients with psoriasis who are treated with systemic and biologic therapies
may have an increased risk of infections, including hepatitis B virus (HBV). Cytokines that …

Background Both the safety and efficacy of biologic therapy may be affected in the presence
of highly prevalent chronic viral hepatitis. Objectives To evaluate the safety and …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

Psoriasis is a chronic inflammatory, immune-mediated disease that affects 1% to 2% of the
world's population. Immunobiological medications are prescribed for certain patients with …

Hepatitis B virus reactivation after ustekinumab treatment: reply from authors Page 1 while
HbsAg is negative in the serum. Occult HBV infection is classified into two groups based on HBV …

5. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, et
al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic …

Introduction This study observed the effectiveness of ustekinumab and reactivation risk of
concurrent latent tuberculosis infection (LTBI) and inactive hepatitis B virus (HBV) infection …

Background This work aimed to investigate the long-term clinical experience with
ustekinumab in cases with psoriasis. Materials and methods This retrospective cohort …